PFE250110C27000
- 0.11
- -0.16-59.26%
Pfizer Newsroom
Pfizer Is Maintained at Neutral by UBS
Pfizer Analyst Ratings
UBS Maintains Pfizer(PFE.US) With Hold Rating, Cuts Target Price to $29
Truist Financial Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $32
Truist Financial Sticks to Its Buy Rating for Pfizer (PFE)
TD Cowen Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $32
Pfizer: Navigating Revenue Challenges and Opportunities With a Hold Rating
A Quick Look at Today's Ratings for Pfizer(PFE.US), With a Forecast Between $29 to $33
Pfizer Price Target Cut to $32.00/Share From $36.00 by Truist Securities
Pfizer Analyst Ratings
A Quick Look at Today's Ratings for Pfizer(PFE.US), With a Forecast Between $28 to $36
Truist Financial Gives a Buy Rating to Pfizer (PFE)
Wells Fargo Adjusts Price Target on Pfizer to $28 From $27, Keeps Equalweight Rating
Cautious Hold Rating for Pfizer Amidst Stable Near-Term Outlook and Long-Term Concerns
Pfizer's Stable Outlook Amid Growth Challenges and Policy Risks Leads to Hold Rating
Pfizer's Balanced Outlook: Hold Rating Amid Uncertainties and Growth Potential
UBS Sticks to Its Hold Rating for Pfizer (PFE)
J.P. Morgan Reaffirms Their Hold Rating on Pfizer (PFE)
Wells Fargo Maintains Pfizer(PFE.US) With Hold Rating, Cuts Target Price to $27
Pfizer (PFE) Gets a Hold From Wells Fargo